SSY GROUP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.76 HKD | 0.00% |
|
+1.50% | -3.85% |
| Apr. 23 | SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator | MT |
| Apr. 16 | SSY Group Logs Nearly 15% Boost in Q1 Profit | MT |
ETFs positioned on SSY Group Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.89% | 4 M€ | -27.92% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.68% | - | |
| 0.00% | 34 M€ | +2.35% | - |
SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Companyâs main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Companyâs products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Companyâs products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.
Sector
Pharmaceuticals
Calendar
2024-05-20
- Final dividend
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.76
HKD
Average target price
6.227
HKD
Spread / Average Target
+30.81%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.85% | 1.8B | |
| +25.61% | 660B | |
| +23.59% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.62% | 219B | |
| -9.04% | 196B | |
| +6.50% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 2005 Stock
- Funds and ETFs SSY Group Limited
